|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial
|
|
Neal Shore, MD, FACS
|
| Alicia Morgans is joined by Neal Shore to discuss his presentation from the 2021 American Urologic Association (AUA) annual meeting on the relationship between PSA response and urinary and bowel adverse events, time to deterioration in the quality of life, and prostate cancer related invasive procedures in the ARAMIS trial.
|
|
|
|
|
|
|
|
|
|
|
|
| Cognitive Assessment in Men with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Randomly Receiving Darolutamide or Enzalutamide in the ODENZA Trial |
| Karim Fizazi, MD, Ph.D. |
| Karim Fizazi joins Alicia Morgans in discussing the 2021 European Society for Medical Oncology (ESMO) presentation of the results from the ODENZA trial comparing darolutamide and enzalutamide, with a focus on cognitive assessment. |
|
|
|
|
|
|
|
|
|
|
|
|
Pain and Symptomatic Skeletal Events Reported in the VISION Trial
|
|
Oliver Sartor, MD
|
| Alicia Morgans and Oliver Sartor discuss additional data from the VISION trial that was recently presented at ESMO 2021. Dr. Sartor discusses the health-related quality of life findings from the VISION trial, specifically pain and symptomatic skeletal events.
|
|
|
|
|
|
|
|
|
|
|
|
|
Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial
|
|
Christian Gratzke, MD
|
| Alicia Morgans is joined by Christian Gratzke to discuss data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting around the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial.
|
|
|
|
|
|
|
|
|
|
|
|
| How Patients Can Support the Qualitative Empirical Data and Strengthen Cancer Health Research |
| Jan Geissler |
| In this presentation, Mr. Jan Geissler, a long-time cancer survivor and patient advocate discussed how qualitative data from patients can strengthen cancer research. He begins by describing the difficult trade-offs that are often the norm for cancer patients: choosing between either proven or unknown therapies that have a range of side effects that can range from bad to ugly. |
|
|
|
|
|
| Health-Related Quality of Life (HRQoL), Pain and Safety Outcomes in the Phase III VISION Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer |
| Karim Fizazi, MD, Ph.D. |
| In this study, Karim Fizazi discusses the health-related quality of life (HRQoL) data from the VISION study of 177Lu-PSMA-617 (Lu-PSMA). The combination of Lu-PSMA and SOC in patients with mCRPC previously treated with an androgen receptor pathway inhibitor and taxane chemotherapy extended OS, delayed rPFS, and was generally well-tolerated. Further, results presented herein support that Lu-PSMA delayed time to worsening in HRQol and pain, and delayed time to first symptomatic skeletal events. |
|
|
|
|
|
|
|
|
|
|
| Time Course Profile of Adverse Events of Interest and Serious Adverse Events with Darolutamide in the ARAMIS Trial
|
| Christian Gratzke, MD
|
| Christian Gratzke presents the results of the analysis of time to adverse events of interest associated with some androgen receptor inhibitors (fatigue, falls, fracture, hypertension, mental impairment, and rash) and the cumulative incidence of these adverse events, grade 3/4 adverse events, and serious adverse events from the ARAMIS trial.
|
|
|
|
|
|
| Impact of Darolutamide on Local Symptoms in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
|
| Neal Shore, MD, FACS
|
| In a podium presentation at the American Urologic Association Annual Meeting, Neal Shore assessed the relationship between prostate-specific antigen (PSA) response and urinary and bowel adverse events (AEs), time to deterioration in quality of life (QoL), and prostate cancer (PC)–related invasive procedures in ARAMIS.
|
|
|
|
|
|
| Hormone Treatment-Related Adverse Events (HTR AEs) with Darolutamide (DARO) in Patients (Pts) with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) from the Phase 3 ARAMIS Study
|
| Karim Fizazi, MD, Ph.D.
|
| In this abstract, Karim Fizazi presents the hormone treatment–related adverse events for darolutamide treatment and characterizes the onset and occurrence over time versus PBO. Based on this analysis, the authors conclude that, consistent with previous safety reports, DARO was well tolerated in patients with nmCRPC. Most HTR AEs occurred at a low incidence with DARO and with similar incidence to that of PBO. HTR AEs showed minimal increase with continued treatment.
|
|
|
|
|
|
| Objective Computerized Cognitive Assessment in Men with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Randomly Receiving Darolutamide or Enzalutamide in the ODENZA Trial |
| Emeline Colomba, MD |
| Emeline Colomba presented results from the ODENZA trial comparing darolutamide and enzalutamide, with a focus on cognitive assessment. In early mCRPC, darolutamide was associated with a statistically significant benefit in verbal learning and verbal memory compared to enzalutamide. |
|
|
|
|
|
|
|
|
|
|
|
